Verition Fund Management
ITOS

Verition Fund Management’s iTeos Therapeutics ITOS Stock Holding History

Verition Fund Management’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-150,648
Closed -$1.5M – 3883
2025
Q2 		$1.5M Buy
150,648
+106,500
+241% +$858K 0.01% 2170
2025
Q1 		$264K Sell
44,148
-54,551
-55% -$401K ﹤0.01% 2921
2024
Q4 		$758K Buy
98,699
+71,901
+268% +$618K ﹤0.01% 2212
2024
Q3 		$274K Sell
26,798
-4,916
-16% -$75K ﹤0.01% 2696
2024
Q2 		$471K Buy
+31,714
New +$454K ﹤0.01% 2081
2023
Q4 		– Sell
-94,824
Closed -$1.04M – 2508
2023
Q3 		$1.04M Sell
94,824
-21,459
-18% -$274K 0.01% 1059
2023
Q2 		$1.54M Buy
+116,283
New +$1.66M 0.02% 794
2022
Q1 		– Sell
-6,435
Closed -$300K – 2871
2021
Q4 		$300K Buy
+6,435
New +$214K ﹤0.01% 1989

Other funds holding ITOS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Verition Fund Management's ITOS Position: Q3 2025 in Review

Verition Fund Management sold out of iTeos Therapeutics (ITOS) in Q3 2025, closing a stake of 150,648 shares — an estimated $1.5M sold.

Verition Fund Management first reported a position in ITOS in Q4 2021 and held it in 8 quarters. The position peaked at $1.54M in Q2 2023. 1 fund tracked by Wall St. Rank holds ITOS as of Q3 2025.

  • Verition Fund Management reported no remaining iTeos Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Verition Fund Management sold 150,648 iTeos Therapeutics shares in Q3 2025, an estimated $1.5M.
  • Verition Fund Management first reported a position in iTeos Therapeutics in Q4 2021 and held it in 8 quarters.
  • Verition Fund Management's iTeos Therapeutics position peaked at $1.54M in Q2 2023.
  • 1 fund tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2025.

Based on Verition Fund Management's 13F filing for Q3 2025, filed 14 Nov 2025.